HARMONY BIOSCIENCES HOLDINGS
NASDAQ: HRMY (Harmony Biosciences Holdings, I)
Last update: 22 hours ago36.89
-1.08 (-2.84%)
| Previous Close | 37.97 |
| Open | 38.00 |
| Volume | 451,422 |
| Avg. Volume (3M) | 585,663 |
| Market Cap | 2,122,377,600 |
| Price / Earnings (TTM) | 11.90 |
| Price / Earnings (Forward) | 10.68 |
| Price / Sales | 2.87 |
| Price / Book | 2.83 |
| 52 Weeks Range | |
| Earnings Date | 28 Oct 2025 |
| Profit Margin | 20.50% |
| Operating Margin (TTM) | 30.45% |
| Diluted EPS (TTM) | 2.62 |
| Quarterly Revenue Growth (YOY) | 19.50% |
| Quarterly Earnings Growth (YOY) | 18.90% |
| Total Debt/Equity (MRQ) | 24.63% |
| Current Ratio (MRQ) | 3.67 |
| Operating Cash Flow (TTM) | 222.67 M |
| Levered Free Cash Flow (TTM) | 143.41 M |
| Return on Assets (TTM) | 12.81% |
| Return on Equity (TTM) | 24.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Harmony Biosciences Holdings, I | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 1.0 |
| Average | 1.13 |
|
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 11.10% |
| % Held by Institutions | 92.80% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Valor Management Llc | 30 Jun 2025 | 6,618,033 |
| Lsv Asset Management | 30 Jun 2025 | 1,488,502 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 61.00 (Oppenheimer, 65.36%) | Buy |
| Median | 55.00 (49.09%) | |
| Low | 48.00 (Truist Securities, 30.12%) | Buy |
| Average | 54.67 (48.20%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 35.05 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 21 Jul 2025 | 48.00 (30.12%) | Buy | 35.25 |
| Deutsche Bank | 10 Jul 2025 | 55.00 (49.09%) | Buy | 34.33 |
| Oppenheimer | 02 Jun 2025 | 61.00 (65.36%) | Buy | 35.56 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |